Taldenaplex 20 - Axio Labs

Tadalafil citrate, marketed as Cialis, was developed in the 1990s by ICOS Corporation and later co-developed with Eli Lilly. Originally explored for cardiovascular uses, it was found to inhibit PDE5, leading to smooth muscle relaxation and improved blood flow for erectile function. Approved in 2003 by the FDA, tadalafil offered a unique advantage: up to 36 hours of action due to its 17.5-hour half-life. Its once-daily dosing, approved in 2008, marked a major shift in ED treatment, offering continuous support for spontaneous sexual activity.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Taldenaplex 20 by Axio Labs, consult with your doctor or healthcare professional.